Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin …

CA Bousman, JM Stevenson… - Clinical …, 2023 - Wiley Online Library
Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake
inhibitors (SSRIs; ie, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and …

Developmental changes in pharmacokinetics and pharmacodynamics

J van den Anker, MD Reed, K Allegaert… - The Journal of …, 2018 - Wiley Online Library
Effective drug therapy to optimally influence disease requires an understanding of a drug's
pharmacokinetic, pharmacodynamic, and pharmacogenomic interrelationships. In …

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake …

JK Hicks, JR Bishop, K Sangkuhl… - Clinical …, 2015 - Wiley Online Library
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major
depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the …

[HTML][HTML] Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation

UM Zanger, M Schwab - Pharmacology & therapeutics, 2013 - Elsevier
Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

PharmVar GeneFocus: CYP2D6

C Nofziger, AJ Turner, K Sangkuhl… - Clinical …, 2020 - Wiley Online Library
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly
polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism …

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update

KR Crews, A Gaedigk… - Clinical …, 2014 - Wiley Online Library
Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome
P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 …

Developmental pharmacokinetics in pediatric populations

H Lu, S Rosenbaum - The Journal of Pediatric …, 2014 - meridian.allenpress.com
Information on drug absorption and disposition in infants and children has increased
considerably over the past 2 decades. However, the impact of specific age-related effects on …

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta …

JD Duarte, CD Thomas, CR Lee… - Clinical …, 2024 - Wiley Online Library
Betablockers are widely used medications for a variety of indications, including heart
failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in …

Tolerance and withdrawal from prolonged opioid use in critically ill children

KJS Anand, DF Willson, J Berger, R Harrison… - …, 2010 - publications.aap.org
OBJECTIVE: After prolonged opioid exposure, children develop opioid-induced
hyperalgesia, tolerance, and withdrawal. Strategies for prevention and management should …

Complexities of CYP2D6 gene analysis and interpretation

A Gaedigk - International review of psychiatry, 2013 - Taylor & Francis
Abstract Cytochrome P450 2D6 (CYP2D6) plays an important role in the metabolism and
bioactivation of about 25% of clinically used drugs including many antidepressants …